ADGC Publications

Found 20 results
Filters: Author is Cruchaga, Carlos  [Clear All Filters]
2018
Blue EE, Bis JC, Dorschner MO, Tsuang DW, Barral SM, Beecham G, Below JE, Bush WS, Butkiewicz M, Cruchaga C et al..  2018.  Genetic Variation in Genes Underlying Diverse Dementias May Explain a Small Proportion of Cases in the Alzheimer's Disease Sequencing Project.. Dement Geriatr Cogn Disord. 45(1-2):1-17.
2017
Rehker J, Rodhe J, Nesbitt RR, Boyle EA, Martin BK, Lord J, Karaca I, Naj A, Jessen F, Helisalmi S et al..  2017.  Caspase-8, association with Alzheimer's Disease and functional analysis of rare variants.. PLoS One. 12(10):e0185777.
Haddick PCG, Larson JL, Rathore N, Bhangale TR, Phung QT, Srinivasan K, Hansen DV, Lill JR, Pericak-Vance MA, Haines J et al..  2017.  A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer's Disease Brains.. J Alzheimers Dis. 56(3):1037-1054.
Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MVictoria, Budde J et al..  2017.  Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.. Acta Neuropathol. 133(5):839-856.
Chapuis J, Flaig A, Grenier-Boley B, Eysert F, Pottiez V, Deloison G, Vandeputte A, Ayral A-M, Mendes T, Desai S et al..  2017.  Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.. Acta Neuropathol. 133(6):955-966.
Jun GR, Chung J, Mez J, Barber R, Beecham GW, Bennett DA, Buxbaum JD, Byrd GS, Carrasquillo MM, Crane PK et al..  2017.  Transethnic genome-wide scan identifies novel Alzheimer's disease loci.. Alzheimers Dement. 13(7):727-738.
2016
Yokoyama JS, Wang Y, Schork AJ, Thompson WK, Karch CM, Cruchaga C, McEvoy LK, Witoelar A, Chen C-H, Holland D et al..  2016.  Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease.. JAMA Neurol. 73(6):691-7.
2015
Escott-Price V, Sims R, Bannister C, Harold D, Vronskaya M, Majounie E, Badarinarayan N, Morgan K, Passmore P, Holmes C et al..  2015.  Common polygenic variation enhances risk prediction for Alzheimer's disease.. Brain. 138(Pt 12):3673-84.
Wang L-S, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JDGonzalez, Cannon-Albright L, Baldwin CT, Zetterberg H et al..  2015.  Rarity of the Alzheimer disease-protective APP A673T variant in the United States.. JAMA Neurol. 72(2):209-16.
2014
Naj AC, Jun G, Reitz C, Kunkle BW, Perry W, Park YSon, Beecham GW, Rajbhandary RA, Hamilton-Nelson KL, Wang L-S et al..  2014.  Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study.. JAMA Neurol. 71(11):1394-404.
Escott-Price V, Bellenguez C, Wang L-S, Choi S-H, Harold D, Jones L, Holmans P, Gerrish A, Vedernikov A, Richards A et al..  2014.  Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease.. PLoS One. 9(6):e94661.
Kauwe JSK, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, Staley LA, Karch CM, Harari O, Cruchaga C et al..  2014.  Genome-wide association study of CSF levels of 59 alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation.. PLoS Genet. 10(10):e1004758.
Benitez BA, Jin SChih, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert J-C, J Gibbs R, Bras J et al..  2014.  Missense variant in TREML2 protects against Alzheimer's disease.. Neurobiol Aging. 35(6):1510.e19-26.
Wetzel-Smith MK, Hunkapiller J, Bhangale TR, Srinivasan K, Maloney JA, Atwal JK, Sa SM, Yaylaoglu MB, Foreman O, Ortmann W et al..  2014.  A rare mutation in UNC5C predisposes to late-onset Alzheimer's disease and increases neuronal cell death.. Nat Med. 20(12):1452-7.
Ramirez A, van der Flier WM, Herold C, Ramonet D, Heilmann S, Lewczuk P, Popp J, Lacour A, Drichel D, Louwersheimer E et al..  2014.  SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.. Hum Mol Genet. 23(24):6644-58.
2013
Cruchaga C, Kauwe JSK, Harari O, Jin SChih, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell D et al..  2013.  GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.. Neuron. 78(2):256-68.
2011
Bailey M, Kauwe JSK, Cruchaga C, McKean D, Mayo K, Bertlesen S, Hinrichs A, Fagan A, Holtzman D, Goate AM.  2011.  Association study of recently reported AD risk variants with cerebrospinal fluid AD biomarker levels. AAIC (ICAD) 2011, Paris, France.
Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BNarayan, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK et al..  2011.  Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.. Nat Genet. 43(5):436-41.
Kauwe JSK, Cruchaga C, McKean D, Bailey M, Patty D, Mayo K, Bertlesen S, Hinrichs A, Fagan A, Holtzman D et al..  2011.  Genome-wide association analyses using cerebrospinal fluid Aβ42 levels as endophenotype for Alzheimer’s disease. ASHG/ICHG 2011 (Montreal, Canada).
Cruchaga C, Kauwe JSK, McKean D, Bailey M, Patty D, Mayo K, Bertlesen S, Hinrichs A, Peskind E, Li G et al..  2011.  Genome-wide association analyses using cerebrospinal fluid tau and phospho-tau and Aβ42 levels as endophenotypes for Alzheimer’s disease. AAIC (ICAD) 2011, Paris, France.